The PCFiT Platform: A Promising Approach for B-Cell Directed Allergy Immunotherapy

Time: 12:00 pm
day: Day Two


  • B-cell targeting fusion proteins (PCFiT™) elicit a potent allergen specific IgG response
  • They are devoid of sensitizing and T-cell activating activity and offer short course, high-dose AIT
  • The approach can be broadly applied to all major allergen sources, clinical proof of concept has been demonstrated